(NYSE: NUVB) Nuvation Bio's forecast annual revenue growth rate of 211.78% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Nuvation Bio's revenue in 2025 is $7,873,000.On average, 3 Wall Street analysts forecast NUVB's revenue for 2025 to be $5,081,198,862, with the lowest NUVB revenue forecast at $3,718,693,828, and the highest NUVB revenue forecast at $6,885,341,122. On average, 2 Wall Street analysts forecast NUVB's revenue for 2026 to be $35,248,001,834, with the lowest NUVB revenue forecast at $29,092,513,645, and the highest NUVB revenue forecast at $41,403,490,024.
In 2027, NUVB is forecast to generate $87,413,012,476 in revenue, with the lowest revenue forecast at $87,413,012,476 and the highest revenue forecast at $87,413,012,476.